## PATENT COOPERATION TREATY

# **PCT**

I	REC'D	2 8 FEB 2005			
	WIPO	PCT			

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

		•				
Applicant's or agent's file reference 100807-1 WO	FOR FURTHER	ACTION	See Form PCT/IPEA/416			
International application No. PCT/GB2004/000550	International filing da 11.02.2004		Priority date (day/month/year) 13.02.2003			
International Patent Classification (IPC) or national classification and IPC A61K31/4745, A61K31/513, A61K31/517						
-						
Applicant						
ASTRAZENECA AB et al						
This report is the international Authority under Article 35 and	preliminary examination transmitted to the applic	report, established by this	International Preliminary Examining			
2. This REPORT consists of a tot			•			
3. This report is also accompanie						
a. D sent to the applicant an	d to the International Bu	reau) a total of sheets, as	s follows:			
sheets of the descri and/or sheets conta						
☐ sheets which super beyond the disclosu Supplemental Box.	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. 1 and the					
b. 🔲 (sent to the International	l Bureau only) a total of	(indicate type and number	of clockwaria namicu(-)			
	b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
4. This report contains indications	relating to the following	items:				
Box No. I Basis of the control in the cont	pinion					
☐ Box No. II Priority						
Box No. III Non-establish     ■      Box No. III Non-establish     Box No. III No. III Non-establish     Box No. III	ment of opinion with reg	ard to novelty, inventive s	tep and industrial applicability			
☐ Box No. IV Lack of unity	of invention					
applicability, (	mations and explanation	(2) with regard to novelty, as supporting such statement	inventive step or industrial ent			
☐ Box No. VI Certain docur						
	ts in the international ap					
Box No. VIII Certain obser	vations on the internatio	nal application				
Date of submission of the demand		Date of completion of this	monet			
		Date of completion of this	report			
24.08.2004		01.03.2005				
Name and mailing address of the international preliminary examining authority:	onal	Authorized Officer				
European Patent Office - P. NL-2280 HV Rijswilk - Pays	Bas	Laharia C	September Personal			
Tel. +31 70 340 - 2040 Tx: 3 Fax: +31 70 340 - 3016	31 651 epo nl	Leherte, C				
1 ax. For 70 340 * 3016		Telephone No. +31 70 340	)-2748			

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000550

_							
_	Bo	x No. I Basis of the report					
1.	. With regard to the language, this report is based on the international application in the language in which it wa filed, unless otherwise indicated under this item.						
		This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:					
		☐ international search (under Rules 12.3 and 23.1(b)) ☐ publication of the international application (under Rule 12.4) ☐ international preliminary examination (under Rules 55.2 and/or 55.3)					
2.	th regard to the <b>elements*</b> of the international application, this report is based on (replacement sheets which we been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this wort as "originally filed" and are not annexed to this report):						
	Des	scription, Pages					
	1-39	as originally filed					
	Cla	ims, Numbers					
	1-14	as originally filed					
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing					
3.		The amendments have resulted in the cancellation of:					
		☐ the description, pages					
		the claims, Nos.					
		☐ the drawings, sheets/figs ☐ the sequence listing (specify):					
		any table(s) related to sequence listing (specify):					
4.		This report has been established as if (some of) the amendments annexed to this report and listed below not been made, since they have been considered to go beyond the distance of the considered to go beyond the considered to go b					
	Sup	had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).					
		the description, pages					
		☐ the claims, Nos. ☐ the drawings, sheets/figs					
	☐ the sequence listing (specify):						
		any table(s) related to sequence listing (specify):					
	*	If item 4 applies, some or all of these sheets may be marked "superseded."					

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000550

	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability							
1.	Th	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:						
	Ø	claims Nos. 14 with respect to	strial applicability					
		because:						
	×	the said international application, or the said claims Nos. 14 with respect to industrial applicability relate to the following subject matter which does not require an international preliminary examination (specify):						
		see separate sheet						
the description, claims or drawings (indicate particular elements below) or said claims Nos. are so that no meaningful opinion could be formed (specify):								
the claims, or said claims Nos. are so inadequately supported by the description that no meanin could be formed.				so inadequately supported by the description that no meaningful opinion				
į		$\Box$ no international search report has been established for the said claims Nos.						
[	J	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:						
		the written form		has not been furnished				
				does not comply with the standard				
		the computer readable form		has not been furnished				
				does not comply with the standard				
Ε	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, on not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.							
	3	See separate sheet for further o	ietail	s				
L	J	See separate sheet for further details						

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No: Claims

1-14

Inventive step (IS)

Yes: Claims

No: Claims 1-14

Industrial applicability (IA)

Yes: Claims

1-13

No: Claims

14 (see separate sheet)

2. Citations and explanations (Rule 70.7):

see separate sheet

PCT/GB2004/000550

## Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 14 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(i) PCT).

#### Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1) The following document is referred to in this communication:

D1: WO 01/32651 A

### 2) NOVELTY

The subject-matter of claims 1-14 is not new in the sense of Article 33 (2) PCT. Document D1 already discloses the combined use of ZD6474 and 5-Fu or CPT-11 in antiangiogenic and/or vascular permeability reducing treatment.

### 3) INVENTIVE STEP

Should the Applicant nevertheless overcome the objections of lack of novelty raised above, then his attention is drawn to the fact that the present claims would not meet the requirements of Article 33(3) PCT, because the subject matter of the claims would not involve an inventive step.

The use of a combination of two or more active ingredients with known identical therapeutic use can only be considered as inventive when a surprising effect, an unexpected high synergistic effect or reduced side effects for example, can be assigned in relation to the claimed therapeutic use. In this respect, the present application lacks supportive evidence as the results of the comparative tests on pages 36 and 39 do not

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/000550

show more then additive effects..

- 4) INDUSTRIAL APPLICABILITY
- 4.1) There are not doubts about the industrial applicability of claims 1-13.
- 4.2) For the assessment of the present claims 14 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.